This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
TASTE was a randomized, parallel-group clinical trial evaluating thrombus aspiration as a procedure in patients with acute myocardial infarction.
| Feature | TASTE |
|---|---|
| NCT ID | NCT01093404 |
| Title | Thrombus Aspiration in Myocardial Infarction |
| Status | COMPLETED |
| Condition | Acute Myocardial Infarction |
| Allocation | RANDOMIZED |
| Design model | PARALLEL |
| Masking | SINGLE |
| Primary purpose | TREATMENT |
| Lead sponsor | Region Örebro County |
2. Clinical Question
Population
Patients with acute myocardial infarction.
Intervention
Thrombus aspiration (procedure).
Comparator
The registry identifies a randomized two-arm comparison; comparator details are not reported in the ClinicalTrials.gov record.
Primary question
Does thrombus aspiration affect the occurrence of all-cause death within 30 days after study inclusion?
3. Trial Design
Enrollment
7243
Randomization
Two arms
Procedure evaluation
30-day assessment
4. Endpoints
| Endpoint | Time frame | Definition |
|---|---|---|
| All-cause death | 30 days | Death from any cause will be registered via national registries during the first 30 days after study inclusion. |
5. Planned Analysis
The ClinicalTrials.gov record lists the primary endpoint as all-cause death at 30 days. No statistical analyses are posted in the registry.
For a randomized trial with a binary mortality endpoint, the planned comparison would typically involve comparing the proportion of deaths between randomized groups using an appropriate hypothesis test or regression-based approach. The analysis would generally preserve the randomized treatment assignment to maintain the advantages of randomization.
Because no formal statistical analyses were posted to ClinicalTrials.gov, estimates, confidence intervals, and p-values for the primary endpoint are not available in the registry record.
6. Statistical Methodology
Randomization and treatment comparison
Randomization creates comparable groups on average and allows differences in outcomes to be interpreted as comparisons between assigned strategies rather than comparisons between self-selected groups.
Binary endpoint framework
For a mortality endpoint, the effect of an intervention may be summarized using measures such as risk difference, risk ratio, or odds ratio, depending on the prespecified analysis approach.
Time frame matters
The primary endpoint was defined over the first 30 days after study inclusion. Short-term mortality endpoints focus interpretation on events occurring during that specified period rather than later outcomes.
7. Statistical Methods Explained
Why does randomization matter?
Randomization reduces systematic differences between treatment groups at baseline, allowing the treatment comparison to be evaluated with less confounding.
Why is all-cause death a binary endpoint?
Each patient contributes an outcome classification: death occurred or death did not occur within the defined 30-day period.
Why are confidence intervals important?
A confidence interval describes uncertainty around an estimated treatment effect. It provides information about precision beyond a single estimate.
Why is the p-value not the same as clinical importance?
A p-value addresses compatibility with a statistical hypothesis under specified assumptions. It does not describe the magnitude of an effect or its clinical relevance.
Why does the analysis population matter?
In randomized trials, preserving assignment in the primary analysis generally maintains the balance created by randomization.
8. Limitations
- The ClinicalTrials.gov record does not report posted statistical analyses, effect estimates, confidence intervals, or p-values.
- The registry record does not report additional endpoint analyses, subgroup analyses, or safety results.
- The registry record does not report details of missing-data handling, multiplicity adjustments, or interim analyses.
9. Why This Trial Matters Statistically
TASTE provides an example of a large randomized cardiovascular trial framework where a procedural intervention is evaluated against a clinically meaningful mortality endpoint.
| Concept | Application |
|---|---|
| Randomization | Two-arm randomized comparison |
| Binary outcome analysis | 30-day all-cause death |
| Clinical endpoint definition | Registry-defined mortality timeframe |
| Statistical uncertainty | Requires confidence intervals around treatment effects |
10. Sources
- ClinicalTrials.gov record: NCT01093404
- PubMed references: